Compositions and methods for enhancing structural and functional nervous system reorganization and recovery

• US 20060104969A1
• Filed: 08/16/2005
• Published: 05/18/2006
• Est. Priority Date: 08/16/2004
• Status: Abandoned Application

• Current Assignee: Brigham and Women's Hospital Incorporated, Massachusetts Institute of Technology
• Original Assignee: Brigham and Women's Hospital Incorporated, Massachusetts Institute of Technology
• Inventors: Sur, Mriganka, Teng, Yang, Oray, Serkan, Majewska, Ania K.
• Application Number:
  US11/205,501
• Publication Number:
  US 20060104969A1
• Time in Patent Office: Days
• US Class Current: 424/94.630
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 33/14 Alkali metal chlorides; Alkaline earth metal chlorides
• CPC Class Codes: A61K 33/30 Zinc; Compounds thereof
• CPC Class Codes: A61K 33/42 Phosphorus; Compounds thereof
• CPC Class Codes: A61K 38/484 Plasmin (3.4.21.7)
• CPC Class Codes: A61K 38/49 Urokinase; Tissue plasminogen activator
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61L 2300/254 Enzymes, proenzymes
• CPC Class Codes: A61L 2300/412 Tissue-regenerating or healing or proliferative agents
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence

Abstract

The present invention provides methods and compositions for enhancing recovery in a subject suffering from damage to the nervous system. In particular, the invention includes a method for promoting recovery and/or reorganization in the nervous system of a subject in need of enhancement of recovery and/or reorganization of the nervous system as a result of ischemic, hemorrhagic, neoplastic, degenerative, or traumatic damage by focally administering a composition comprising a proteolysis-enhancing agent such as tissue plasminogen activator (tPA), plasmin, or a PAI inhibitor to the nervous system of the subject. In some embodiments an additional active agent is also administered. The composition can be delivered using a variety of techniques including injection, via infusion pump, from an implantable microchip, or using a polymeric delivery vehicle. The composition can be administered, for example, to one or more subdivisions or areas of the brain, the spinal cord, or to one or more nerves or nerve tracts innervating diverse regions of the body. The invention also includes a drug delivery device for implantation into the nervous system to promote nervous system reorganization and/or recovery following ischemic, hemorrhagic, neoplastic, traumatic or degenerative damage, the drug delivery device comprising a biocompatible polymer and a proteolysis-enhancing agent such as tissue plasminogen activator (tPA), plasmin, or a PAI inhibitor, wherein the proteolysis-enhancing agent is released from the polymer in an amount effective to promote structural reorganization of the nervous system. In some embodiments the biocompatible polymer is a hydrogel.

Claims

1. A method for promoting recovery or reorganization in the nervous system of a subject comprising the step of:

focally administering a composition comprising a proteolysis-enhancing agent to the central or peripheral nervous system of a subject in need of enhancement of recovery or reorganization of the nervous system as a result of ischemic, hemorrhagic, neoplastic, degenerative, or traumatic damage to the nervous system.

2. The method of claim 1, wherein the proteolysis-enhancing agent is a protease.

3. The method of claim 1, wherein the proteolysis-enhancing agent is plasmin, a plasminogen activator, or an inhibitor of an endogenous plasminogen activator inhibitor.

4. The method of claim 1, wherein the proteolysis-enhancing agent is tissue plasminogen activator (tPA).

5. The method of claim 1, wherein the proteolysis-enhancing agent is plasmin.

6. The method of claim 1, wherein the proteolysis-enhancing agent promotes degradation of a component of the extracellular matrix.

7. The method of claim 1, wherein the proteolysis-enhancing agent directly or indirectly degrades fibrin.

8. The method of claim 1, wherein focal administration is performed between 1 day and 1 month following a specific damaging event.

9. The method of claim 1, wherein focal administration is performed between 1 week and 1 month following a specific damaging event.

10. The method of claim 1, wherein focal administration is performed at least 1 month following a specific damaging event.

11. The method of claim 1, wherein focal administration is performed after the subject has reached a plateau of functional recovery following a specific damaging event.

12. The method of claim 1, wherein the damage involves the central nervous system.

13. The method of claim 12, wherein the damage involves the brain.

14. The method of claim 12, wherein the damage involves the spinal cord.

15. The method of claim 1, wherein the damage involves the peripheral nervous system.

16. The method of claim 1, wherein focal administration is achieved by implanting into the subject a drug delivery device that releases the proteolysis-enhancing agent over a period of time at or in the vicinity of a desired location in the central or peripheral nervous system.

17. The method of claim 16, wherein the desired location is an area of ischemic, hemorrhagic, neoplastic, degenerative, or traumatic damage in the central or peripheral nervous system, or is an oppositely located brain hemisphere.

18. The method of claim 16, wherein the drug delivery device comprises a pump.

19. The method of claim 16, wherein the drug delivery device comprises a biocompatible polymer.

20. The method of claim 19, wherein the polymer is biodegradable.

21. The method of claim 1, wherein the composition comprises a plurality of polymeric microparticles or nanoparticles having the proteolysis-enhancing agent associated therewith.

22. The method of claim 1, wherein the proteolysis-enhancing agent is delivered in a solution that forms a gel following contact with physiological fluids.

23. The method of claim 1, wherein the proteolysis-enhancing agent is delivered in an amount effective to promote structural reorganization of synaptic connections, increase formation of new synaptic connections, increase dendritic spine motility, promote growth of axons, or any combination of the foregoing.

24. The method of claim 1, wherein the proteolysis-enhancing agent is delivered in an amount effective to promote growth or sprouting of axons, promote structural reorganization of synaptic connections, increase formation of new synaptic connections, increase dendritic spine motility, or any combination of the foregoing over a period of at least 1 week.

25. The method of claim 1, wherein the proteolysis-enhancing agent is delivered in an amount effective to promote growth or sprouting of axons, promote structural reorganization of synaptic connections, increase formation of new synaptic connections, increase dendritic spine motility, or any combination of the foregoing over a period of at least 1 month.

26. The method of claim 1, wherein the proteolysis-enhancing agent is delivered in an amount effective to promote growth or sprouting of axons, promote structural reorganization of synaptic connections, increase formation of new synaptic connections, increase dendritic spine motility, or any combination of the foregoing over a period of at least 3 months.

27. The method of claim 1, wherein the proteolysis-enhancing agent is delivered in an amount effective to promote growth or sprouting of axons, promote structural reorganization of synaptic connections, increase formation of new synaptic connections, increase dendritic spine motility, or any combination of the foregoing over a period of at least 1 year.

28. The method of claim 1, wherein the composition is administered by injecting or infusing it at or in the vicinity of a desired location in the central or peripheral nervous system.

29. The method of claim 28, wherein the desired location is an area of ischemic, hemorrhagic, neoplastic, degenerative, or traumatic damage in the central or peripheral nervous system, or is an oppositely located brain hemisphere.

30. The method of claim 1, wherein the composition is administered intrathecally.

31. The method of claim 1, wherein the composition further comprises an agent selected from the group consisting of neural growth enhancing agents, which are optionally selected from among neurotransmitters or analogs thereof, neurally active growth factors, neural signaling molecules, neurally active small molecules, and neurally active metals.

32. The method of claim 1, further comprising the step of:

engaging the subject in a program of rehabilitation designed to promote functional recovery following ischemic, hemorrhagic, neoplastic, or traumatic damage to the nervous system, wherein the subject is so engaged during at least part of the time interval during which the agent is administered or during which the agent remains active in the nervous system of the subject.

33. A method of treating a subject in need of enhancement of recovery or reorganization in the nervous system as a result of ischemic, hemorrhagic, neoplastic, degenerative, or traumatic damage comprising focally administering a composition comprising a proteolysis-enhancing agent to the central or peripheral nervous system of the subject.

34. The method of claim 33, wherein the damage is due to a stroke.

35. The method of claim 33, wherein the damage is to the spinal cord.

36. The method of claim 33, wherein the damage is to one or more nerves supplying a muscle, lung, or other organ of the body.

37. The method of claim 36, wherein the muscle is the diaphragm.

38. The method of claim 33, wherein the proteolysis-enhancing agent is selected from the group consisting of plasmin, a plasminogen activator, and an inhibitor of an endogenous plasminogen activator inhibitor.

39. The method of claim 33, wherein the agent is tissue plasminogen activator (tPA).

40. The method of claim 33, wherein the agent is plasmin.

41. The method of claim 33, wherein focal delivery is achieved by implanting a drug delivery device comprising a biocompatible polymer and the proteolysis-enhancing agent into the nervous system of the subject at or in the vicinity of an area of damage.

42. The method of claim 33, wherein the composition further comprises an agent selected from the group consisting of neurotransmitters or analogs thereof, neurally active growth factors, modulators of synaptic signaling molecules, neurally active small molecules, neurally active metals, and cells.

43. The method of claim 42, wherein the cells are stem cells.

44. A drug delivery device for implantation into the nervous system of a subject to promote recovery or reorganization in the nervous system following ischemic, hemorrhagic, neoplastic, degenerative, or traumatic damage to the nervous system, the drug delivery device comprising:

a biocompatible polymer; and

a proteolysis-enhancing agent, wherein the proteolysis-enhancing agent is released from the polymer in an amount effective to promote recovery or reorganization in the nervous system of the subject.

45. The drug delivery device of claim 44, wherein the biocompatible polymer is biodegradable.

46. The drug delivery device of claim 44, wherein the agent is plasmin, a plasminogen activator, or an inhibitor of an endogenous plasminogen activator inhibitor.

47. The drug delivery device of claim 44, wherein the agent is tissue plasminogen activator (tPA).

48. The drug delivery device of claim 44, wherein the agent is plasmin.

49. The drug delivery device of claim 44, further comprising a neural growth enhancing agent, wherein the neural growth enhancing agent is optionally selected from the group consisting of neurotransmitters or analogs thereof, neurally active growth factors, and neurally active small molecules, and neurally active metals.

50. A composition comprising a proteolysis-enhancing agent selected from the group consisting of:

tissue plasminogen activator, plasmin, and inhibitors of tissue plasminogen activator inhibitors and further comprising a neural growth enhancing agent, wherein said agent is optionally selected from the group consisting of;

neurotransmitters or analogs thereof, neurally active growth factors, modulators of synaptic signaling molecules, neurally active small molecules, neurally active metals, and cells.